GEN Exclusives

More »

GEN News Highlights

More »
Jul 30, 2013

Study: Diabetes Drug Helps Mice Live Longer, More Healthfully

  • Scientists have long sought drugs to extend life. One of the places they are searching is on the pharmacy shelf. Drugs like the immunosuppressant rapamycin have been shown to extend life in lab mice.

    Today, writing in Nature Communications, researchers from the National Institute on Aging (NIA) and their colleagues present data reaffirming that diabetes drug metformin ought to be added to the theoretical checklist of compounds that appear to stave off aging, extending the lives of animals administered them.

    Testing two doses of metformin in male C57BL/6 mice, NIA’s Alejandro Martin-Montalvo, Ph.D., and his colleagues found that the diabetes drug increased both healthspan and longevity. That is, not only did the mice live longer, they also lived more healthfully.

    In their paper, Dr. Martin-Montalvo et al., note that treating male mice with metformin mimicked some of the benefits observed with caloric restriction—like improved physical performance, increased insulin sensitivity, and reduced low-density lipoprotein and cholesterol levels—without reducing intake. They also note that, at a molecule level, metformin increases antioxidant protection and AMP-activated protein kinase activity, reducing both the accumulation of oxidative damage and chronic inflammation.

    “Our results indicate that these actions may contribute to the beneficial effects of metformin on healthspan and lifespan,” the researchers write. “These findings are in agreement with current epidemiological data and raise the possibility of metformin-based interventions to promote healthy aging,” they add.

    Still, they note, further research is required. Dr. Martin-Montalvo and his colleagues caution that the levels of metformin observed in the lab mice were about 10 times higher than they appear in diabetes patients taking the drug.

    “Metformin improves healthspan and lifespan in mice” was published July 30 in Nature Communications.


Readers' Comments

Posted 07/31/2013 by Tom Hennessy

A few curious things here are , metformin lowers iron levels , iron restriction mimics 'the effects of csaloric restriction,' and iron deprivation is being used in diabetes and nafld , the same diseases metformin is used? Could it be , as is hypothesised , increased iron leads to diabetes and metformin works by removing the elevated iron?
"findings strongly suggest that the age-related accumulation in muscle iron contributes to increased oxidative stress and sarcopenia, and that caloric restriction effectively attenuates these negative effects.”.
"Does metformin improve polycystic ovary syndrome symptoms through reduction in body iron stores? "
"Iron Depletion Therapy for Type 2 DM and NAFLD".

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Connectomics Advocacy

How might connectomics maintain lasting support?